Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 360-degree synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence and prevalence of ovarian cancer
3.2.1.2 Growing awareness and screening programs
3.2.1.3 Increasing research and development activities
3.2.1.4 Technological advancements in ovarian cancer diagnostics
3.2.2 Industry pitfalls & challenges
3.2.2.1 High treatment costs
3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Instruments/analyzers
5.3 Consumables
Chapter 6 Market Estimates and Forecast, By Diagnostic Tests, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Imaging test
6.2.1 Ultrasound
6.2.2 CT scan
6.2.3 MRI scan
6.2.4 PET scan
6.2.5 Other imaging tests
6.3 Blood test
6.3.1 CA125 (Cancer antigen 125)
6.3.2 HER2 (Human epidermal growth factor receptor 2)
6.3.3 BRCA (Breast cancer gene)
6.3.4 CEA (Carcinoembryonic antigen)
6.3.5 ER & PR (Estrogen receptor and progesterone receptor)
6.3.6 KRAS mutation
6.3.7 Other blood tests
6.4 Biopsy
6.5 Other diagnostic tests
Chapter 7 Market Estimates and Forecast, By Cancer Type, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Epithelial tumor
7.3 Germ cell tumor
7.4 Stromal cell tumor
7.5 Other cancer types
Chapter 8 Market Estimates and Forecast, By End-Use, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Diagnostic laboratories
8.4 Diagnostic imaging centers
8.5 Cancer research institutes
8.6 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 Agilent Technologies
10.3 Canon Medical Systems Corporation
10.4 Danaher Corporation
10.5 F. Hoffmann-La Roche Ltd.
10.6 Fujirebio Diagnostics
10.7 GE HealthCare Technologies Inc.
10.8 Illumina Inc.
10.9 Myriad Genetics
10.10 Philips Healthcare
10.11 Positron Corporation
10.12 Qiagen N.V.
10.13 Quest Diagnostics
10.14 Siemens Healthineers AG
